Clinical trials: Atypical Hyperplasia
Complex Atypical Hyperplasia, Endometrial Cancer
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial…
- Trial name
- NCT05483023
- Testing
- 18F-fluorofuranylnorprogesterone PET / MRI
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Women At Risk: The High Risk Breast Cancer Program
The purpose of this study is to increase understanding of women who are at high risk for developing breast cancer. Data from this group will be collected and entered into a registry.
- Trial name
- WAR (NCT01034891)
- Where
- 2 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- New York Presbyterian Hospital
Endometrial Hyperplasia
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia
The purpose of this research study is to compare the uterus tissue of women who receive an intrauterine system to treat their endometrial hyperplasia with the uterine tissue of women who receive megestrol acetate to treat their…
- Trial name
- NCT04897217
- Testing
- Megestrol Acetate, Levonorgestrel Drug Implant
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several…
- Trial name
- FHIR (NCT05810025)
- Testing
- RealRisks
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Columbia University
Breast Cancer, Precancerous Condition
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
RATIONALE: Polyunsaturated fatty acids are important for normal growth and development. One type, called omega-3 fatty acids (found in fish, fish oil, and some other foods), may affect the growth of abnormal breast cells.
- Trial name
- NCT00627276
- Testing
- omega-3 fatty acid
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05178498
- Testing
- Follow-Up, Physical Examination, Questionnaire Administration
- Where
- United States
- Volunteers
- 960 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Precancerous Condition
Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy
RATIONALE: Broccoli sprout extract supplements may slow the growth of tumor cells or abnormal cells and may be an effective treatment for ductal carcinoma in situ and/or atypical ductal hyperplasia.
- Trial name
- NCT00843167
- Testing
- broccoli sprout extract
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Obesity, Overweight
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of mazdutide combined with a levonorgestrel-releasing intrauterine…
- Conditions
- Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
- Trial name
- MELIA (NCT07781150)
- Testing
- Mazdutide(Dual GLP-1R/GCGR Agonist), Levonorgestrel-releasing intrauterine system
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Tongji Hospital
Breast Cancer
Markers for Breast Cancer
This study will analyze blood samples to identify substances that are associated with the development of breast cancer. It will determine if: Women who are diagnosed with a benign breast condition that is related to a…
- Trial name
- NCT00339248
- Where
- United States
- Volunteers
- 2,632 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.
- Trial name
- NCT00291122
- Testing
- celecoxib 400 mg BID
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Endometrial Hyperplasia
Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women
The purpose of this study is to compare the efficacy of the Levonorgestrel releasing Intrauterine System (Mirena) and Norethisterone Acetate for treatment of non-atypical endometrial hyperplasia in perimenopausal women.
- Trial name
- NCT01499602
- Testing
- LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland, Norethisterone Acetate tablets
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Mansoura University
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers.
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Trial name
- NCT04496739
- Testing
- Cancer Educational Materials, Decision Aid, Interview
- Where
- 97 sites in United States, Guam
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network
Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation
- Trial name
- NCT05647109
- Testing
- No intervention
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Peking University People's Hospital
Complex Endometrial Hyperplasia With Atypia, Grade 1 Endometrial Endometrioid Adenocarcinoma
Improving the Treatment for Women With Early Stage Cancer of the Uterus
Currently the standard treatment for early stage endometrial cancer or endometrial hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and removal of both ovaries.
- Trial name
- feMMe (NCT01686126)
- Testing
- Levonorgestrel, Metformin
- Where
- 17 sites in Australia, New Zealand
- Volunteers
- 165 people
- Sponsor
- Queensland Centre for Gynaecological Cancer
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
Atypical Endometrial Hyperplasia, Obese
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)
- Conditions
- Atypical Endometrial Hyperplasia, Obese, Fertility Issues
- Trial name
- NCT04683237
- Testing
- Liraglutide Injection, Megestrol Acetate 160 MG
- Sponsor
- Xiaojun Chen
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia
Molecular Breast Imaging in Women With Atypia and LCIS
We aim to determine if Molecular Breast Imaging (a new nuclear medicine technique developed at Mayo) can identify malignant breast lesions in women who have atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular…
- Conditions
- Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
- Trial name
- NCT00620087
- Testing
- Molecular Breast Imaging, Screening Mammography
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Neoplasms
Endometrial Cell Collection With the PadKit
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed.
- Trial name
- NCT06464107
- Testing
- PadKit™ from Preprogen
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Hackensack Meridian Health
Breast Cancer, Invasive Carcinoma
X-Ray Mammography Standard of Care Protocol
Background: X-ray mammography is the standard method for breast cancer screening. It is a noninvasive test using x-rays to take pictures of breast tissue and detect any abnormalities.
- Conditions
- Breast Cancer, Invasive Carcinoma, In Situ Carcinoma, Fibrocystic Changes
- Trial name
- NCT01052740
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Endometrial Cancer, Atypical Endometrial Hyperplasia
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods.
- Trial name
- NCT07892755
- Where
- China
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Guizhou Provincial People's Hospital